ArriVent BioPharma has postponed its Phase 3 trial from early to mid-2026 due to slower event accumulation, not operational or enrollment issues. The company ended Q1 with $326.4 million in cash, extending its financial runway from Q3 2027 to Q4 2027, which lowers near-term funding risks. Meanwhile, its Shanghai Allist operations show strong commercial momentum in China, and the ARR-002 product adds a new growth opportunity. These developments support ArriVent's late-stage development and commercialization efforts.
ImPact Biotech announced updated Phase 3 ENLIGHTED trial results showing 70% complete response in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Padeliporfin VTP. The treatment demonstrated durable effects, with 85.7% of...
Google is integrating its AI-powered Gemini technology with Fitbit data in a new Google Health app, aiming to enhance fitness tracking and coaching. This innovation is expected to extend to Google's upcoming smart glasses, potentially offering real-t...
Major League Baseball has introduced the Automatic Ball-Strike (ABS) system, developed with T-Mobile, to review close pitch calls in real time using 5G and Hawk-Eye cameras. The system, now in 29 US stadiums, allows players to challenge umpire calls ...
The business development company (BDC) sector has faced significant challenges from mid-2025 through early 2026 due to factors like spread tightening. However, analyst Samuel Smith believes the sector is poised for a turnaround, with certain BDC comp...
The Bill Gates Foundation Trust has sold its entire Microsoft stock position, ending decades of ownership. This move reflects practical portfolio management, diversification, and funding needs for philanthropy rather than a lack of confidence in Micr...
